Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...
U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...
The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...
ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.
Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
23andMe CEO Anne Wojcicki is attempting to buy her company back for a mere $42 million. It’s a fraction of the company’s ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...